Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections.

It is a prodrug which is converted in vivo into the active form afabicin desphosphono (Debio 1452) which acts as an inhibitor of the staphylococcal enoyl-acyl carrier protein reductase (FabI) enzyme.

It has shown similar efficacy in clinical trials to established drugs such as vancomycin, but has not yet been approved for clinical use.

[1][2][3][4][5][6]